Artelo Biosciences releases peer-reviewed study on fatty acid binding proteins

Written by Emily J. Thompson, Senior Investment Analyst

ARTL-7.18%

Updated: Nov 04 2025

0mins

Publication Announcement: Artelo Biosciences has published a peer-reviewed article titled "The Emerging Role of Fatty Acid Binding Protein 3 in Cancers" in Drug Discovery Today, led by Dr. George Warren.
Research Focus: This article is the third in a series of reviews discussing the protumoral roles of FABP isoforms 3, 5, and 7 in cancer biology.
Company Commitment: Gregory Gorgas, CEO of Artelo, emphasized the company's dedication to developing innovative therapeutics to meet unmet medical needs through ongoing research on FABPs.
Future Plans: Artelo aims to advance its lead program, ART26.12, which targets FABP5 for pain treatment, while also exploring the potential of its FABP inhibitor portfolio in various cancers and diseases linked to lipid signaling dysregulation.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like ARTL with instant alerts to capture every critical market movement.

ARTL

$1.68+Infinity%1D

Analyst Views on ARTL

About ARTL

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.